Theophilos Tzaridis

Sigmund Freud Str. 25
Bonn, NW 53127, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 47 publications

NAMPT activation uncovers a senescence-specific vulnerability and promotes healthy aging in combination with NAM.

NAMPT activation uncovers a senescence-specific vulnerability and promotes healthy aging in combination with NAM.

Journal: bioRxiv : the preprint server for biology

Published: August 20, 2026

CD155 regulates tumor growth and susceptibility to T cell mediated killing in diffuse midline glioma.

CD155 regulates tumor growth and susceptibility to T cell mediated killing in diffuse midline glioma.

Journal: Neuro-oncology

Published: February 13, 2026

ONC206 demonstrates potent anti-tumorigenic activity and is a potential novel therapeutic strategy for high-risk medulloblastoma.

ONC206 demonstrates potent anti-tumorigenic activity and is a potential novel therapeutic strategy for high-risk medulloblastoma.

Journal: bioRxiv : the preprint server for biology

Published: November 19, 2025

Interferon Restores Antigen Presentation and Sensitizes Medulloblastoma to T Cell Killing.

Interferon Restores Antigen Presentation and Sensitizes Medulloblastoma to T Cell Killing.

Journal: bioRxiv : the preprint server for biology

Published: November 19, 2025

ONC206 demonstrates potent anti-tumorigenic activity and is a potential novel therapeutic strategy for high-risk medulloblastoma.

ONC206 demonstrates potent anti-tumorigenic activity and is a potential novel therapeutic strategy for high-risk medulloblastoma.

Journal: Neuro-oncology

Published: September 18, 2025

ONC206 demonstrates potent antitumorigenic activity and is a potential novel therapeutic strategy for high-risk medulloblastoma.

ONC206 demonstrates potent antitumorigenic activity and is a potential novel therapeutic strategy for high-risk medulloblastoma.

Journal: Neuro-oncology

Published: September 18, 2025

Honeybadger, a micropeptide encoded by an alternative PVT1 transcript, is a critical negative regulator of RAS-MAPK signaling in MYC-driven tumors.

Honeybadger, a micropeptide encoded by an alternative PVT1 transcript, is a critical negative regulator of RAS-MAPK signaling in MYC-driven tumors.

Journal: Genes & development

Published: September 15, 2025

Editorial: Advancing precision therapies in glioblastoma.

Editorial: Advancing precision therapies in glioblastoma.

Journal: Frontiers in oncology

Published: August 07, 2025

Synergistic RAS-MAPK and AKT Activation in MYC-Driven Tumors via Adjacent PVT1 Rearrangements.

Synergistic RAS-MAPK and AKT Activation in MYC-Driven Tumors via Adjacent PVT1 Rearrangements.

Journal: bioRxiv : the preprint server for biology

Published: March 03, 2025

Efficacy of vaccination therapy in newly diagnosed and recurrent glioblastoma patients: a meta-analysis.

Efficacy of vaccination therapy in newly diagnosed and recurrent glioblastoma patients: a meta-analysis.

Journal: BMC cancer

Published: January 16, 2025

Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with lomustine/temozolomide.

Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with lomustine/temozolomide.

Journal: Neuro-oncology

Published: October 01, 2024

Systematic design of combination therapy by targeting master regulators of coexisting diffuse midline glioma cell states.

Systematic design of combination therapy by targeting master regulators of coexisting diffuse midline glioma cell states.

Journal: Nature genetics

Published: September 16, 2024

Showing 1-12 of 47

Last Updated: 09/26/2026